Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Composiciones de nanocápsulas para liberación controlada de agentes de interés terapéutico

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20180223001
Publicado:
05/04/2018
Caducidad:
06/04/2019
Resumen:
Un centro de investigación y una universidad españoles que trabajan en investigación biomédica en el campo de biomateriales y biomedicina han desarrollado composiciones de nanocápsulas capaces de liberar agentes de interés terapéutico con efecto cinético controlado, prolongado y sostenible en el tiempo, reduciendo la administración total requerida. Las cápsulas permiten la liberación sostenida de la enzima alojada y ofrecen una mejora terapéutica en comparación con las terapias actuales, reduciendo la necesidad de realizar inyecciones repetidas o de altas dosis de colagenasa. El centro de investigación busca compañías farmacéuticas y biotecnológicas que trabajen con biomoléculas, nanocápsulas y nanopartículas interesadas en establecer acuerdos de licencia.


Details

Tittle:
Nanocapsule compositions for the controlled released of agents of therapeutic interest
Summary:
A Spanish research centre, in collaboration with a Spanish university, works on biomaterials. They have developed a nanocapsule compositions capable of releasing agents of therapeutic interest with a controlled kinetic and a prolonged and sustainable effect over time; reducing the overall administration required. They are looking for license agreement.
Description:
Fibrosis is a common lesion in different pathological conditions and it is defined by the excessive accumulation of collagen and other extracellular matrix proteins in the connective tissue of different organs where it causes organ dysfunction. Collagen corresponds around of 30% of all proteins in humans, and is the major extracellular protein of different organs such as the skin, cartilage, bones, teeth and cornea.

To prevent this collagen accumulation, proteases are used. Proteases target many substrates, thus inflicting changes in distinct biological processes correlated with fibrosis.

At present, there is still a need to provide protease carriers or vehicles capable of achieving a constant and continuous release of the proteases encapsulated within at therapeutic doses during a sufficient period of time for the treatment of diseases which require a sustained protease administration during treatment periods greater than one week.

A Spanish research team from a of a university hospital and a Spanish university are working on biomedical research in biomaterials and biomedicine. The hospital team works on the rheumatology and dermatology department and the university professor on smart biomaterials for pharmaceutical used. They have developed a nanocapsule compositions capable of releasing agents. The agents, proteases of therapeutic interest, can be released with a controlled kinetic and a prolonged and sustainable effect over time.

The controlled and sustained released solves the above mentioned problems for treatments that last more than one week. It provides sustained release polymeric nanocapsules capable of releasing proteases such as collagenase with a controlled kinetic and a prolonged and sustainable effect over time.

The team is looking for license agreement. They are looking for pharmaceutical or biotechnology companies working on biomolecules, nanocapsules or nanoparticules, to license the patent. It will be desired if they have interest in fibrosis treatment.
Advantages and Innovations:
This novel nanocapsule composition is adaptable to encapsulate and effectively deliver agents of therapeutic interest reducing the overall administration required. These capsules provide a sustained release of the housed enzyme thus providing a therapeutic improvement in comparison to current therapies thus decreasing the need for repeated injections or high collagenase doses.
Stage of Development:
Field tested/evaluated
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
European patent applied.

Partner sought

Type and Role of Partner Sought:
They are looking for a company working on pharmaceutical or biotechnology sector. They should have the capacity to develop nanocapsule.

The roll will be to adapt the nanocapsules to their needs and bring it to market,

The Spanish groups are looking for license agreement, but if needed they could cooperate with the company in any further development.

Client

Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06004 Micro y nanotecnología relacionada con las ciencias biológicas
06001015 Productos farmacéuticos / medicamentos
06002003 Tecnología de enzimas